Healthcare / Medical DevicesMilan
$74.72
+1.24 (+1.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.4B · quality 83.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$130.1B
P/E
24.4x
↑EV/EBITDA
11.3x
↓ROE
12.5%
↑Gross Margin
56.4%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.5%
FCF CAGR
-1.8%
FCF margin
16.7%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.33B · net income $6.52B · FCF $7.39B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.33B | $44.33B | $41.95B | $40.11B | $43.65B |
| Net Income | $6.52B | $6.52B | $13.40B | $5.72B | $6.93B |
| EBITDA | $12.07B | $12.07B | $10.79B | $10.54B | $12.13B |
| EPS | 3.72 | 3.72 | 7.64 | 3.26 | 3.91 |
| Gross Margin | 56.4% | 56.4% | 55.4% | 55.2% | 56.1% |
| Operating Margin | 18.2% | 18.2% | 16.3% | 16.2% | 19.2% |
| Net Margin | 14.7% | 14.7% | 31.9% | 14.3% | 15.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.32 | 0.40 | 0.48 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.39B | $7.39B | $6.35B | $5.06B | $7.80B |
| Returns | |||||
| ROE | 12.5% | 12.5% | 28.1% | 14.8% | 18.9% |
| Valuation | |||||
| P/E | 24.42 | 24.42 | — | — | — |
| EV/EBITDA | 11.26 | 11.26 | — | — | — |
| P/B | 2.51 | 2.51 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 5.7% | 5.7% | 4.6% | -8.1% | — |
| EPS Growth | -51.3% | -51.3% | 134.4% | -16.6% | — |
| Dividend Yield | 2.9% | 2.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.2%
EPS terminal req.
$6.63
Spread vs growth
-72.6%
5Y implied EPS CAGR
16.6%
EPS terminal req.
$8.02
Spread vs growth
-67.9%
10Y implied EPS CAGR
13.3%
EPS terminal req.
$12.92
Spread vs growth
-64.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.1%
Start / end P/E
15.3x → 20.1x
EPS bridge
7.64 → 3.72
Residual
-16.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.